General form of registration statement for all companies including face-amount certificate companies

Common Stock, Preferred Stock and Convertible Preferred Stock (Details)

v3.21.2
Common Stock, Preferred Stock and Convertible Preferred Stock (Details) - USD ($)
 1 Months Ended 2 Months Ended 6 Months Ended 12 Months Ended
Nov. 30, 2020
Feb. 29, 2020
Aug. 31, 2019
Oct. 31, 2018
Oct. 31, 2019
Jun. 30, 2021
Jun. 30, 2020
Dec. 31, 2020
Dec. 31, 2019
Sep. 30, 2019
Common Stock, Preferred Stock and Convertible Preferred Stock (Details) [Line Items]                    
Common stock, shares authorized           500,000,000   500,000,000 500,000,000  
Common stock par value (in Dollars per share)           $ 0.0001   $ 0.0001 $ 0.0001  
Lieu of issuing shares (in Dollars)           $ 7,000   $ (52,044)    
Shares of common stock               1,666,667    
Warrants to purchase shares         2,130,115          
Exercisable and expire   In February 2020, Private Augmedix raised $0.5 million in cash proceeds through issuance of 173,752 shares of Series B to certain existing shareholders and warrants to purchase up to 57,338 shares of Series B at a price of $2.88 per share, are immediately exercisable and expire in September 2029. The warrants have an exercise price of $39.76 per share and $0.86 per share, are immediately exercisable and expire in August 2028 and August 2024, respectively.              
Preferred stock, shares authorized           10,000,000   10,000,000 10,000,000  
Preferred stock, par value (in Dollars per share)           $ 0.0001   $ 0.0001 $ 0.0001  
Issued shares of convertible preferred stock           14,804,274   14,804,274    
Fair value of warrant liability (in Dollars)   $ 95,478       $ 186,000 $ 743,837 $ 71,635  
Issuance costs (in Dollars)               $ 52,893    
Exercisable and expire     At the Effective Time of the Merger, the warrants to purchase shares of Series B were converted to warrants to purchase 2,767,836 shares of common stock at a price of $2.88 per share, are immediately exercisable and expire in September 2029.              
Sub Agreement [Member]                    
Common Stock, Preferred Stock and Convertible Preferred Stock (Details) [Line Items]                    
Warrants to purchase shares   2,767,836                
Exercise price per share (in Dollars per share)   $ 2.88                
Private Placement [Member]                    
Common Stock, Preferred Stock and Convertible Preferred Stock (Details) [Line Items]                    
Shares of common stock               8,472,188    
Purchase price (in Dollars per share)               $ 3.00    
Aggregate gross proceeds (in Dollars)               $ 25,400,000    
Issuance costs (in Dollars) $ 160,000             $ 3,000,000.0    
Warrants to purchase shares 53,333             164,745    
Exercise price per share (in Dollars per share) $ 3.00             $ 3.00    
Un accredited Investor [Member]                    
Common Stock, Preferred Stock and Convertible Preferred Stock (Details) [Line Items]                    
Lieu of issuing shares (in Dollars)               $ 555,174    
Lieu of issuing shares (in Dollars)           $ 600,000        
Majority Shareholder [Member]                    
Common Stock, Preferred Stock and Convertible Preferred Stock (Details) [Line Items]                    
Lieu of issuing shares (in Dollars)               $ 31,527    
Non-employee [Member]                    
Common Stock, Preferred Stock and Convertible Preferred Stock (Details) [Line Items]                    
Warrants to purchase shares     4,208 1,052            
Exercise price per share (in Dollars per share)     $ 0.86 $ 39.76            
Series B Preferred Stock [Member]                    
Common Stock, Preferred Stock and Convertible Preferred Stock (Details) [Line Items]                    
Warrants to purchase shares   57,338     1,751,279          
Exercise price per share (in Dollars per share)   $ 2.88                
Cash proceeds (in Dollars)   $ 499,999     $ 15,271,440          
Issued shares of convertible preferred stock   173,752     5,306,910     1,281,631    
Fair value of warrant liability (in Dollars)               $ 3,281,216    
Issuance costs (in Dollars)   $ 4,017                
Issuance costs (in Dollars)   $ 4,000                
Series B Preferred Stock [Member] | Sub Agreement [Member]                    
Common Stock, Preferred Stock and Convertible Preferred Stock (Details) [Line Items]                    
Warrants to purchase shares   57,338 580,383   57,338 580,383       2,130,115
Series B Preferred Stock [Member]                    
Common Stock, Preferred Stock and Convertible Preferred Stock (Details) [Line Items]                    
Exercise price per share (in Dollars per share)         $ 2.88          
Common Stock [Member]                    
Common Stock, Preferred Stock and Convertible Preferred Stock (Details) [Line Items]                    
Common stock share issued           2,166,667   2,166,667    
Lieu of issuing shares (in Dollars)               $ 217    
Shares of common stock 666,667             10,000,000    
Aggregate gross proceeds (in Dollars) $ 2,000,000.0                  
Issued shares of convertible preferred stock                  
Warrant [Member]                    
Common Stock, Preferred Stock and Convertible Preferred Stock (Details) [Line Items]                    
Shares of common stock       91            
Exercisable and expire   In February 2020, Private Augmedix raised $499,999 in cash proceeds through issuance of 173,752 shares of Series B to certain existing shareholders and warrants to purchase up to 57,338 shares of Series B at a price of $2.88 per share, are immediately exercisable and expire in September 2029.                
Fair value of warrant liability (in Dollars)   $ 100,000